Tirzepatide and GLP-1 receptor agonists are replacing older treatments, marking a shift in how diabetes and weight loss are ...

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years ...

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in ...

After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering medications (GLMs) and among adults without diabetes prescribed ...

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in with the new.

In this retrospective cohort study, tirzepatide dispensations were found to have increased significantly following approval ...

Skye shares surge after new data shows nimacimab reduces weight over 30% with tirzepatide, with stable potency and promising ...

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

New research to be presented at the European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that around ...